



Edelris Announces Research Collaboration Agreement with Pfizer Inc.

Tuesday, January 31, 2017 - 08:00am

Lyon (France) - January 31, 2017 - Edelris s.a.s., a leading medicinal chemistry company focused on applying its EDEN (Edelris Discovery ENgine) technology toward the generation of innovative small molecule leads, today announced the signing of a research collaboration agreement with Pfizer Inc. (NYSE: PFE).

Under the terms of the agreement, Edelris will apply its large, diverse and tractable small molecule library platform (Keymical Space™) as well as its organic, high-throughput and medicinal chemistry expertise to collaborate with Pfizer towards the identification of novel leads against Pfizer-selected targets. The financial terms of the agreement were not disclosed

“Edelris has spent the past decade charting untapped areas of biorelevant chemical space, and has developed efficient ways to mine this resource” said Jean-Yves Ortholand, Chief Executive Officer of Edelris. “We are excited to challenge this space containing very fresh and innovative chemical matter with some important and potentially therapeutically relevant targets selected by leaders in the pharmaceutical industry such as Pfizer.”

Tony Wood, Senior Vice President and Head of Medicinal Sciences, Pfizer said, “We look forward to working with Edelris to explore the use of their natural product-inspired technology to potentially access novel chemical leads.”

About Edelris

EDELIRIS is a MedChem-oriented Research & Services based company, dedicated to the design and production of innovative, therapeutically relevant, natural product-like screening compounds and topologically diverse fragments for FBLD. Aiming at the acceleration of the hit/lead discovery process in pharmaceutical and biotech research organizations, EDELIRIS uses its track-proven chemistry and drug discovery expertise to provide novelty to its customers with exclusive or nonexclusive small molecules, with efficient hit/lead optimization capabilities and with reliable NP total synthesis/derivatives synthesis/analoging services. Customers from pharmaceutical and biotechnology companies worldwide have recognized the value and specificity of Edelris' offer, benefitting from its track-proven MedChem services and its innovative NP-like Keymical Fragments™ and Keymical Collections™.

Press contact

Dr Jean-Yves Ortholand, CEO Edelris Tel: + 33 437 561 903 Email: jean-yves.ortholand@edelris.com